| P/E (FY) | — | Sales (TTM) | CAD 24.5M |
| Earnings (TTM) | -CAD 30.2M | ROE | — |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $63.5M | Trading Days | 215 |
| 52W High | 2.99 |
| 52W Low | 0.99 |
| % Off High | −54.52% |
| YTD | −25.27% |
| Ann. Volatility (1Y) | 99.29% | Ann. Volatility (3Y) | 99.29% |
| Sharpe (1Y) | 0.03 | Sharpe (3Y) | 0.03 |
| Max Drawdown (1Y) | −63.31% | Max Drawdown (3Y) | −63.31% |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| PMVP | PMV Pharmaceuticals, Inc. | $62.9M | — |
| MNOV | MEDICINOVA INC | $65.0M | — |
| TLPH | TALPHERA, INC. | $65.4M | — |
| CYPH | CYPHERPUNK TECHNOLOGIES INC. | $66.2M | 8.9 |
| ACRV | Acrivon Therapeutics, Inc. | $66.8M | — |
| RNTX | Rein Therapeutics, Inc. | $66.9M | — |
| PLRX | PLIANT THERAPEUTICS, INC. | $66.9M | — |
| RFL | Rafael Holdings, Inc. | $67.1M | — |
| CING | Cingulate Inc. | $60.0M | — |
| LIXT | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | $59.9M | — |
| OSTX | OS Therapies Inc | $68.1M |
| XBIT | XBiotech Inc. | $68.9M | — |
